Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


FDA May Emerge From Zohydro Approval Purgatory in October

This article was originally published in RPM Report

Executive Summary

FDA could get relief this autumn from a year of political controversy stemming from the approval of Zohydro, thanks to two abuse-deterrent hydrocodone applications in the works from Purdue and Zogenix. 


Related Content

Seeking Guidance On Abuse-Deterrence: Sponsors Fall Short, Congress Urges Action
Zogenix Zohydro Launch Will Test FDA’s Balanced Approach On Opioid Pain Reviews


Related Companies




Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts